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ABSTRACT
Histamine plays an important role in the development of 
asthmatic symptoms. Diamine oxidase (DAO histaminase), 
which inactivates histamine, is located in the intestine and 
kidney and is released into plasma. Plasma DAO activity in 
asthmatic children was measured by a recently developed
high performance liquid chromatographic method using his-
tamine as the DAO substrate. Diamine oxidase activity was 
higher in severely asthmatic children than in those with mild 
asthma. A time course study during the acute exacerbation 
phase revealed that DAO activity rose during acute asth-
matic attacks and then decreased gradually over several 
days. Although the mechanisms of plasma DAO activity 
increase during acute asthmatic attacks could not be 
explained, data showed that plasma DAO activity is an 
important index of histamine metabolism in asthmatics and 
may relate to some mechanisms of acute exacerbation of 
airway inflammation. Consequently, fluctuations in plasma 
DAO can be used as one of various indices of instability in 
management of asthma.
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INTRODUCTION
It has recently become clear that asthma is a chronic eosinophilic
inflammatory disease and many investigators are concentrating 
on the study of activation mechanisms of eosinophils and lym-
phocytes. They suggest that the late asthmatic response is more 
important than the immediate asthmatic response in generating 
symptoms of natural acute exacerbations of asthma. But the
immediate asthmatic response almost always develops upon 
encountering the pathogenic allergens, resulting in histamine 
being released from mast cells. There are many reports about
the role of histamine in asthmatics, including studies of histamine 
in plasma or urine and histamine metabolites in urine.1-3 But, to 
the best of our knowledge, there are no reports about plasma
(serum) histamine destroying enzyme in asthmatics, although
there are some reports that serum DAO4 or histamine destroying 
factors increases after anaphylaxy in mammals. Therefore, by 
taking measurements of plasma DAO activity, we aimed to 
determine the histamine kinetics in asthmatic children.
METHODS
Materials
Fifteen asthmatic children (7 male, 8 female) were enrolled in 
the study to compare the severity of asthmatic attack with DAO 
activity. Heparinized venous blood was drawn during acute 
asthmatic attacks. Attack severity was categorized by Mitsui's
symptom score: severe attack≧4, mild attack≦3.6 Another 16
asthmatic children (8 male, 8 female) were enrolled in the study 
to compare DAO activity with severity of asthma where the 
severity of asthma was categorized by the Japanese Society of 
Allergology criteria. These criteria consist of a combination of
attack severity and frequency. In this group, heparinized venous
blood was drawn on non-attack days. Finally, seven asthmatic 
children (6 male, 1 female) were enrolled in the time-course 
study. Samples were taken during acute asthmatic attacks, then
on the first day and on the seventh day of the convalescent 
period (no pulmonary additive sounds). 
 Plasma was separated from the heparinized blood immedi-
ately after blood sampling and kept at -25℃ until DAO mea-
surement.
Measurement of diamine oxidase
Plasma was mixed with one-nineteenth volume of 100mmol/L 
phosphate potassium buffer (pH 7.0) including 0.01mmol/L his-
tamine (final concentration). Aminoguanidine (0.001mmol/L; a
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Fig. 1 Determination of diamine oxidase (DAO) activity by HPLC 
method.
Fig. 2 Diamine oxidase (DAO) activity from asthmatics with acute 
attacks.
Fig. 3 Diamine oxidase (DAO) activity from asthmatics without acute 
attacks.
Fig. 4 Change in diamine oxidase (DAO) activity from acute attacks 
phase through convalescence.
specific inhibitor against DAO) was added in the negative control 
assay. Perchloric acid (final concentration 3%) was added after
incubation for 1000min at 37℃ and histaminewas measured by
high performance liquid chromatography.7 The difference in hist-
amine concentration between the sample and the negative con-
trol (Fig. 1) is the measure of DAO activity (pmol histamine 
destruction/min/mL plasma).
Statistical analysis
Student's t-test was used to examine differences. Paired t-test 
was used in the time-course study. Significance was determined 
at the 0.01 level.
RESULTS
Plasma DAO activity during acute asthmatic attacks was slightly
higher in severe attacks (0.57±0.20pmol/min/mL) than in
mild ones (0.38±0.18pmol/min/mL), but this difference was
not significant (P<0.10; Fig. 2). Figure 3 shows DAO activity at 
the remission phase in 16 asthmatic patients. Six patients had 
mild asthma and 10 patients had moderate or severe asthma. 
Diamine oxidase activity was clearly higher in moderately or
severely asthmatic children (0.15±0.05pmol/min/mL) than in
those having mild cases (0.41±0.16pmol/min/mL; P<0.01).
%FEV1 and FEV1% was found to be 101.8±13.9 and 86.8±
5.7% in ild asthmatics, and 96.4±17.8 and 76.9±8.9% in
modera e and severe asthmatics, respectively. The time-course 
of DAD activity from the attack phase through to recovery is 
shown in Fig. 4. Diamine oxidase activity decreased gradually 
from the time of the acute attacks to the seventh day of conva-
lescence. A statistically significant difference (P<0.01) in DAD 
activity was found to exist between the acute attacks and the sev-
enth day. Measurements of DAD activity were found to be 0.56
±17pmol/min/mL during acute attacks, and 0.51±0.33
and 0.38±0.22pmol/min/mL on the first and seventh day of
convalescence, respectively.
DISCUSSION 
Histamine is the first chemical mediator to be incriminated as a 
bronchoconstrictor substance in asthma. Its importance in immedi-
ate asthmatic response is clear, but its importance in late asthmatic 
response is controversial.8-10 It has become clear that other chemi-
cal mediators such as leukotrienes, prostaglandins, thromboxanes 
nd platelet activating factor also play an important role in acute 
asthma ic attacks. They probably operate in a complex network.
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The new antihistamines that block histamine at the H1-receptor 
level again demonstrated the importance of histamine in acute 
asthmatic attacks.11,12 Histamine is metabolized by histamine N-
methyltransferase (HMT) or DAO and excreted into the urine in the 
form of N-methyl histamine, N-methyl imidazole acetic acid, imi-
dazole acetic acid and imidazole acetic acide riboside.13 The stud-
ies of these urinary metabolites are important to determine the 
histamine kinetics. However, by studying enzyme activity, we 
intended to determine the histamine kinetics in asthmatics. The rel-
ative roles of HMT and DAO in the metabolism of endogenous his-
tamine have not yet been established.14 Although it has been 
generally accepted in the past that HMT works predominantly in 
the central nervous system and DAO in the peripheral organs,15 
some recent reports showed the importance of HMT in the air-
ways.16,17 Further, Lowhagen et al. reported that urinary excretion 
of methyl histamine and 1-methyl-4-imidazole acetic acid, HMT 
metabolites were increased during acute asthma in intrinsic adult 
asthmatics.18 On the other hand, HMT can work only in cells with 
co-factor, S-adenosylmethionine, but DAO can work in both cells 
and plasma; and we suppose that this plays an important role in 
histamine catabolism in asthmatics. In this context, we first took 
measurements of plasma DAD activity both during acute asth-
matic attacks and in non-attack periods in asthmatic children in 
order to study histamine kinetics in asthmatics. 
 Although we have no data about plasma DAD activity in 
healthy children, the normal levels for adults and infants are
0.262±0.211 pmol/min/mL plasma (mean±SD, n=178)
and 0.145±0.120 pmol/min/mL plasma (mean±SD, n=10),
respectively. Diamine oxidase activity in mildly asthmatic children 
in the non-attack phase was within the normal range. However, 
DAO activity in moderately or severely asthmatic children in the 
non-attack phase was higher. Diamine oxidase activity during 
acute asthmatic attacks was higher than normal and higher dur-
ing severe attacks than during mild ones. The time-course study of 
DAO activity for acute asthmatic attacks through to convales-
cence showed that DAO activity decreased gradually after recov-
ery of about 1 week.
 At present, we do not know the mechanism by which the 
plasma DAO activity increases during asthmatic attacks, but we 
believe there are two possibilities: (i) heparin released from 
bronchial mucosal mast cells with histamine induces the release 
of DAO from the small intestine; or (ii) activated eosinophils (and 
probably neutrophils) increase in blood during acute asthmatic 
attacks and release DAO, as it has been reported that DAO 
activity in eosinophils increases in active asthma.19 Although we
must study DAO together with plasma histamine, urinary hista-
mine metabolites, HMT and histidine decarboxylase to clarify the 
histamine kinetics in asthmatic children, our preliminary data 
show that plasma DAO activity is one of the important factors in 
histamine metabolism and that the stability of asthma manage-
ment can be assessed by plasma DAO activity levels.
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